Amphastar Pharmaceuticals Gross Profit 2012-2024 | AMPH
Amphastar Pharmaceuticals gross profit from 2012 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Amphastar Pharmaceuticals Annual Gross Profit (Millions of US $) |
2023 |
$351 |
2022 |
$249 |
2021 |
$200 |
2020 |
$143 |
2019 |
$132 |
2018 |
$107 |
2017 |
$91 |
2016 |
$104 |
2015 |
$77 |
2014 |
$51 |
2013 |
$87 |
2012 |
$90 |
2011 |
$28 |
2009 |
$48 |
Amphastar Pharmaceuticals Quarterly Gross Profit (Millions of US $) |
2024-06-30 |
$95 |
2024-03-31 |
$90 |
2023-12-31 |
$96 |
2023-09-30 |
$108 |
2023-06-30 |
$73 |
2023-03-31 |
$74 |
2022-12-31 |
$71 |
2022-09-30 |
$59 |
2022-06-30 |
$63 |
2022-03-31 |
$56 |
2021-12-31 |
$56 |
2021-09-30 |
$51 |
2021-06-30 |
$47 |
2021-03-31 |
$45 |
2020-12-31 |
$37 |
2020-09-30 |
$37 |
2020-06-30 |
$33 |
2020-03-31 |
$37 |
2019-12-31 |
$33 |
2019-09-30 |
$35 |
2019-06-30 |
$32 |
2019-03-31 |
$31 |
2018-12-31 |
$35 |
2018-09-30 |
$29 |
2018-06-30 |
$26 |
2018-03-31 |
$17 |
2017-12-31 |
$20 |
2017-09-30 |
$21 |
2017-06-30 |
$27 |
2017-03-31 |
$23 |
2016-12-31 |
$20 |
2016-09-30 |
$28 |
2016-06-30 |
$32 |
2016-03-31 |
$25 |
2015-12-31 |
$33 |
2015-09-30 |
$18 |
2015-06-30 |
$13 |
2015-03-31 |
$13 |
2014-12-31 |
$12 |
2014-09-30 |
$12 |
2014-06-30 |
$15 |
2014-03-31 |
$13 |
2013-12-31 |
$20 |
2013-09-30 |
$20 |
2013-06-30 |
$27 |
2013-03-31 |
$20 |
2012-12-31 |
$52 |
2012-09-30 |
$57 |
2012-06-30 |
$49 |
2012-03-31 |
$46 |
2011-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$2.469B |
$0.644B |
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|